دورية أكاديمية
أعرض في EDS

Identifying Barriers to Buprenorphine Treatment for Patients with Opioid Use Disorder Among Anesthesiologists and Pain Practitioners: A Survey Study.

التفاصيل البيبلوغرافية
العنوان: Identifying Barriers to Buprenorphine Treatment for Patients with Opioid Use Disorder Among Anesthesiologists and Pain Practitioners: A Survey Study.
المؤلفون: John S; From the Department of Social, Behavioral, and Health Education Sciences, Emory University Rollins School of Public Health, Atlanta, GA (SJ); Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA (DWB); Atlanta VA Healthcare System, Atlanta, GA (SP); Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA (SP)., Boorman DW, Potru S
المصدر: Journal of addiction medicine [J Addict Med] 2023 Mar-Apr 01; Vol. 17 (2), pp. e94-e100. Date of Electronic Publication: 2022 Aug 24.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wolters Kluwer Health, Inc Country of Publication: United States NLM ID: 101306759 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1935-3227 (Electronic) Linking ISSN: 19320620 NLM ISO Abbreviation: J Addict Med Subsets: MEDLINE
أسماء مطبوعة: Publication: [Alphen aan den Rijn, the Netherlands] : Wolters Kluwer Health, Inc.
Original Publication: Hagerstown, MD : Lippincott Williams & Wilkins
مواضيع طبية MeSH: Buprenorphine*/therapeutic use , Chronic Pain*/drug therapy , Acute Pain*/drug therapy , Opioid-Related Disorders*/drug therapy, Male ; Humans ; United States ; Anesthesiologists ; Opiate Substitution Treatment ; Practice Patterns, Physicians' ; Surveys and Questionnaires
مستخلص: Objective: The aim of the study is to investigate barriers to opioid use disorder (OUD) care among acute and chronic pain physicians and advanced practice providers, including hypothesized barriers of lack of interest in OUD care and stigma toward this patient population.
Methods: The study used an anonymous 16-item online survey through Google Forms. Respondents were 153 health practitioners across the United States and Canada, all of whom are registered in one of several pain or anesthesia professional societies. Data were analyzed with descriptive and categorical statistics.
Results: The most common barriers include "lack of appropriate clinical environment for prescribing by both acute and chronic pain practitioners" (48%) and "lack of administrative/departmental support" (46%). A total of 32% of respondents reported that OUD care was important but they were not interested in doing more, while 28% of practitioners believed that they treat patients with OUD differently than others in a negative way. More males reported "difficulty" in treating OUD as a barrier (45% vs 25%). Chronic pain practitioners reported poor payor mix as a barrier twice as often as their acute pain colleagues. In free response, lack of multidisciplinary OUD care was a notable barrier.
Conclusions: The top barriers to OUD treatment were clinical environment, departmental support, difficulty in treating the condition, and payor mix, supporting the hypotheses. Given an OUD patient scenario, 55% of acute pain physicians and 73% of chronic pain physicians expressed a willingness to prescribe buprenorphine.
Competing Interests: The authors report no conflicts of interest.
(Copyright © 2022 American Society of Addiction Medicine.)
References: Ahmad FB, Rossen LM, Sutton P. Products—vital statistics rapid release—provisional drug overdose data. CDC . Published 2021. Available at: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm . Accessed August 23, 2021.
Hedegaard H, Miniño AM, Warner M. Products—data briefs—number 329—November 2018. Available at: https://www.cdc.gov/nchs/products/databriefs/db329.htm . Accessed August 23, 2021.
SAMHSA. TIP 63: Medications for opioid use disorder; 2021. Available at: https://store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document/PEP21-02-01-002 . Accessed August 16, 2022.
Lipari RN, Park-Lee E. Key substance use and mental health indicators in the United States: results from the 2019. National Survey on Drug Use and Health . 2020. Available at: https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP20-07-01-001-PDF.pdf . Accessed August 16, 2022.
Huhn AS, Dunn KE. Why aren’t physicians prescribing more buprenorphine? J Subst Abuse Treat . 2017;78:1.
Huxtable CA, Roberts LJ, Somogyi AA, et al. Acute pain management in opioid-tolerant patients: a growing challenge. Anaesth Intensive Care . 2011;39(5):804–823.
Mackey K, Veazie S, Anderson J, et al. Evidence brief: barriers and facilitators to use of medications for opioid use disorder. Evidence Brief: Barriers and Facilitators to Use of Medications for Opioid Use Disorder . Washington (DC): Department of Veterans Affairs (US); 2019. PMID: 31670926.
National Academies of Sciences, Engineering, and Medicine. Medications for Opioid Use Disorder Save Lives. Washington, DC: he National Academies Press; 2019. Available at: https://nap.nationalacademies.org/catalog/25310/medications-for-opioid-use-disorder-save-lives . Accessed August 16, 2022.
Helfand M, Mackey K, Veazie S, Anderson J, Bourne D, Peterson K. Evidence brief: barriers and facilitators to use of medications for opioid use disorder authors: evidence synthesis program evidence brief: barriers and facilitators to use of medications for OUD evidence synthesis program; 2019.
Sdrulla AD, Chen G. The multidisciplinary approach to the management of substance abuse. Substance Abuse . 2015;193–207.
Yeboah-Sampong S, Weber E, Friedman S. Legal action center | emergency: hospitals can violate federal law by…. Legal Action Center. 2021. Available at: https://www.lac.org/resource/emergency-hospitals-can-violate-federal-law-by-denying-necessary-care-for-substance-use-disorders-in-emergency-departments . Accessed August 22, 2021.
White SR, Bird SM, Merrall ELC, et al. Drugs-related death soon after hospital-discharge among drug treatment clients in Scotland: record linkage, validation, and investigation of risk-factors. PLoS One . 2015;10(11):e0141073.
Kennedy-Hendricks A, Busch SH, McGinty EE, et al. Primary care physicians’ perspectives on the prescription opioid epidemic. Drug Alcohol Depend . 2016;165:61–70.
Whitfield M. Influence of implicit—bias training on the cultural competency of police officers—ProQuest. 2019. Available at: https://scholarworks.waldenu.edu/cgi/viewcontent.cgi?article=8374&context=dissertations . Accessed August 19, 2021.
Muncan B, Walters SM, Ezell J, et al. “They look at us like junkies”: influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City. Harm Reduction J . 2020;17(1):1–9.
Khanna IK, Pillarisetti S. Buprenorphine—an attractive opioid with underutilized potential in treatment of chronic pain. J Pain Res . 2015;8:859–870.
Alex E. Woodruff MTLBESASWAO. dismantling buprenorphine policy can provide more comprehensive addiction treatment. NAM Perspect . 2019.
Webster L, Gudin J, Raffa RB, et al. Understanding buprenorphine for use in chronic pain: expert opinion. Pain Med . 2020;21(4):714–723.
Han B, Compton WM, Blanco C, et al. Prescription opioid use, misuse, and use disorders in U.S. adults: 2015 National Survey on Drug Use and Health. Ann Intern Med . 2017;167(5):293–301.
Wakeman SE, Barnett ML. Primary care and the opioid-overdose crisis—buprenorphine myths and realities. N Engl J Med . 2018;379(1):1–4.
Kohan L, Potru S, Barreveld AM, et al. Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel. Reg Anesth Pain Med . 2021;46(10):840–859.
المشرفين على المادة: 40D3SCR4GZ (Buprenorphine)
تواريخ الأحداث: Date Created: 20220824 Date Completed: 20230316 Latest Revision: 20230401
رمز التحديث: 20230403
DOI: 10.1097/ADM.0000000000001066
PMID: 36001078
قاعدة البيانات: MEDLINE
الوصف
تدمد:1935-3227
DOI:10.1097/ADM.0000000000001066